

ACP Clinical Guidelines 2017 - Athena

Screening for future fall risk

Screening for future fall risk

Description

Measure identifies patients 65 years of age and older who were screened for future fall risk at least once within 12 months.

Patient Identification

Age: 65+

Encounter: An encounter in the last 12 months

Not included in population: Patients indicated as not ambulatory under the social history question, "Is the patient ambulatory?"

Measure Satisfaction

Measure is satisfied if a patient has been screened for future fall risk at least once during the past 12 months.

This can be documented by one of the following:

- Completing a Morse Fall Risk screening questionnaire during an encounter
- Documenting a score for a STEDI Stop Falls screening questionnaire during an encounter
- Documenting a score for a Hendrich II Fall Risk screening questionnaire during an encounter
- Documenting a score for a Schmid Fall Risk screening questionnaire during an encounter
- Billing a relevant CPT II code for fall risk assessment (*1100F, 1101F, 3288F*)
- Manually checking off that a fall risk assessment has been completed and entering in the date in the Quality Management section

[Learn more about this measure](#)

Developer

National Committee for Quality Assurance

Release/Revision Date

04/01/2014

Bibliographic Citation

Centers for Disease Control and Prevention. 2012. "Falls Among Older Adults: An Overview." (February 29)
<http://www.cdc.gov/HomeandRecreationalSafety/Falls/adultfalls.html>

athena updated: 3/2016

Influenza Vaccination (Aug - Mar)

Influenza Vaccination (Aug - Mar)

Description

Measure identifies patients 18 years of age and older who received an influenza vaccine during the current flu season (August - March).

Patient Identification

Age: 18+

Encounter: An encounter in the last 24 months

Measure Satisfaction

Measure is satisfied if the patient received an influenza vaccine during the current flu season.

[Learn more about this measure](#)

Developer

Centers for Disease Control and Prevention (CDC)

Release/Revision Date

08/06/2015

Bibliographic Citation

Centers for Disease Control and Prevention. Prevention and Control of Seasonal Influenza with Vaccines: What You Should Know for the 2016-2017 Influenza Season. August 2016.

athena updated: 10/2016

Pneumonia Vaccination (PCV13 and PPSV23)

Pneumonia Vaccination (PCV13 and PPSV23)

Description

This measure identifies patients 65 years of age and older who have received their 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine in accordance with the Advisory Committee on Immunization Practices (ACIP) administration schedules.

Patient Identification

Age: 65+

Encounter: An encounter during the reporting period

Measure Satisfaction

Measure is satisfied if the patient receives one PCV13 vaccination and one PPSV23 vaccination in accordance with ACIP recommended vaccination schedules. All administered vaccines must be documented in the Vaccines section of the patient's health history or in an encounter.

Information regarding dosing schedules:

Dosing Schedule 1

- Dose 1- PCV13: ≥ 65 years of age
- Dose 2- PPSV23: 1 year or more after dose 1*

Dosing Schedule 2

- Dose 1- PPSV23: ≥ 65 years of age
- Dose 2- PCV13: 1 year or more after dose 1

Dosing Schedule 3

- Dose 1- PPSV23: < 65 years of age
- Dose 2- PCV13: ≥ 65 years of age and at least 1 year after dose 1
- Dose 3- PPSV23: 1 year or more after dose 2, and 5 or more years after dose 1

Dosing Schedule 4

- Dose 1- PCV13: ≤ 65 years of age
- Dose 2- PPSV23: ≥ 65 years of age and at least 1 year or more after dose 1

*The CDC recommends for adults aged 65 years and older with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants, that the recommended interval between PCV13 followed by PPSV23 is greater than or equal to 8 weeks.

[Learn more about this measure](#)

Developer

Advisory Committee on Immunization Practices (ACIP)

Release/Revision Date

12/02/2016

Bibliographic Citation

Centers for Disease Control and Prevention. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2015.

athena updated: 1/2016

BMI Screening

Body Mass Index (BMI) Screening

Description

Measure identifies patients 18 years and older who had their body mass index (BMI) documented during the past 24 months.

Patient Identification

Age: 18+

Encounter: Any encounter during the reporting period

Not included in population: Patients with diagnosis of pregnancy in the past 24 months

Measure Satisfaction

Measure is satisfied for patients who had a calculated BMI in the Vitals section of a relevant encounter, or a documented BMI diagnosis during the past 24 months.

[Learn more about this measure](#)

Developer

National Committee for Quality Assurance (NCQA)

Release/Revision Date

10/01/2015

Bibliographic Citation

Healthcare Effectiveness Data and Information Set (HEDIS). 2016. Adult BMI Assessment (ABA).

athena updated: 12/2015

Tobacco Cessation

Tobacco Cessation

Description

Measure identifies patients 18 years of age and older who are identified as current tobacco users and received tobacco cessation counseling or therapy.

Patient Identification

Age: 18+

Encounter: Any encounter in the last 12 months

Encounter Information: Response to a global Social History question (*Smoking Status, Smoking - How much?, Smoked since age, Tobacco use, chewing tobacco*) indicates patient uses tobacco

Measure Satisfaction

Measure is satisfied if there is new prescription or an active prescription on the patient's medication list for pharmacologic therapy, for smoking cessation, or an order for smoking cessation patient information in the past 24 months.

The measure can also be satisfied manually by checking the box in the Results column and entering the date when the smoking cessation counseling was provided.

[Learn more about this measure](#)

Developer

United States Preventive Services Task Force

Release/Revision Date

09/01/2015

Bibliographic Citation

Final Recommendation Statement: Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions. U.S. Preventive Services Task Force. October 2015.

<http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions1>

athena updated: 04/2017

Depression screening and follow-up

Screening for clinical depression and follow-up

Description

Measure identifies patients 12 years of age and older who have been screened for clinical depression using a standardized depression screening tool, and if positive, a follow-up plan is documented.

Patient Identification

Age: 12+

Encounter: An encounter in the past 12 months (90801, 90802, 90804-90815, 90862, 92557, 92567, 92568, 92590, 92625, 92626, 96150, 96151, 97003, 99201-99205, 99212-99215, 99241-99245, 99251-99255, 99358, 99359, 99381-99387, 99391-99397, G0101, G0402, G0438, G0439, G0444)

Not included in the population: Patients who have an active diagnosis of major depression or bipolar disorder during their encounter

Measure Satisfaction

Measure is satisfied if there is a completed questionnaire for depression documented during an encounter. If positive, a follow-up plan must be documented.

Depression cutoff scores:

PHQ-2: ≥ 3

PHQ-4: ≥ 3

PHQ-9: ≥ 10

Geriatric Depression Scale: ≥ 5

Pediatric Symptom Checklist-17: ≥ 15

Center for Epidemiologic Studies - Depression: ≥ 16

Edinburgh Postnatal Depression Scale: ≥ 13

Beck Depression Inventory: ≥ 17

Follow-up plan entails one or more of the following:

- Referral order for depression
- Depression medication order

If these cannot be found in the clinical encounter, the measure can still be satisfied by manually indicating the result and follow-up action for a depression screen on the patient's Quality Management Tab.

[Learn more about this measure](#)

Developer

The United States Preventive Services Task Force

Bibliographic Citation

Final Recommendation Statement: Depression in Adults: Screening. U.S. Preventive Services Task Force. November 2016. <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/depression-in-adults-screening1>

Colorectal cancer screening

Colorectal cancer screening

Description

Measure identifies patients 50 through 75 years of age who received a colorectal cancer screening.

Patient Identification

Age: 50-75

Encounter: Any encounter during the measurement period

Not included in population: Patients with a current or previous diagnosis of colorectal cancer, or patients with a total colectomy billed (*CPT: 44150-44158, 44210-44212*), or total colectomy documented in the patient's Surgical history as an active surgical history question.

Measure Satisfaction**Measure is satisfied by any of the following:**

Order: An order and a result received for any of the following colorectal cancer screenings

Surgical History: Documenting any of the following screenings in the Procedure section of the patient's Surgical History as an active surgical history question

CPT Code: Billing one of the CPT codes associated with each procedure

CPTII Code: Billing CPTII code 3017F

GYN History: Documenting in GYN History the *Date of Last Colonoscopy* or *Colonoscopy* as a structured date in the last 10 years

Manual Assertion: Manually selecting the type of screening in the Quality tab of the patient's chart and entering the date when the screening was performed

1. Fecal occult blood test during the past year

- CPT: 82270, 82274, G03282. Flexible sigmoidoscopy during the past 5 years
- CPT: 45330-45335, 45337-45342, 45345-45347, 45349, 45350, G01043. Colonoscopy during the past 10 years
- CPT: 44388-44394, 44397, 44401-44408, 45355, 45378-45393, 45398, G0105, G01214. FIT-DNA test (Cologuard) during the past 3 years
- CPT: 81528, G04645. Computed tomography (CT) colonography during the past 5 years
- CPT: 74263

[Learn more about this measure](#)

Developer

United States Preventive Services Task Force (USPSTF)

Release/Revision Date

06/01/2016

Bibliographic Citation

Final Update Summary: Colorectal Cancer: Screening. U.S. Preventive Services Task Force. June 2016.
<https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/colorectal-cancer-screening2>

athena updated: 4/2017

Breast Cancer Screening

Breast Cancer Screening (Mammogram)

Description

Measure identifies women 50 through 74 years of age during the reporting period who had a mammogram to screen for breast cancer within the past 24 months, with a 3 month grace period.

Patient Identification

Age: 50-74

Gender: Female

Encounter: An encounter in the last 24 months

Not included in population: Patients who have had two unilateral mastectomies (*CPT: 19180, 19200, 19220, 19240, 19303, 19304, 19305, 19306, 19307*), or a bilateral mastectomy or total mastectomy as documented in the patient's Surgical History*

Measure Satisfaction

Measure is satisfied by one of the following:

- The receipt of a result for a mammogram imaging order within the past 27 months
 - Documenting a **mammogram** or **mammography** in the Procedure section of the patient's Surgical History within the past 27 months*
 - Documenting the **Most Recent Mammogram** or **Date of Last Mammogram** in GYN History as a structured date in the past 27 months
 - Checking the box in the Results column and entering the date when the breast cancer screening was performed
- *To pull from a patient's Surgical History the procedure must be documented as an active surgical history question.

Note: Electronic results will automatically replace any manual data entry. The 27 month satisfaction period can be customized at the specialty or patient level.

[Learn more about this measure](#)

Developer

United States Preventive Services Task Force

Release/Revision Date

12/04/2009

Bibliographic Citation

U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med* 2009;151:716-726.

Note: Statin therapy for the Prevention and Treatment of Cardiovascular Disease - There is no guideline listed in Athena "Clinical Guidelines" to address this ACO measures specifically; various guidelines for statin use in cardiovascular disease and for lipid screening/management for prevention and for a variety of diagnoses (e.g. cardiovascular disease, diabetes, hypertension, IVD, high risk drug use).

HbA1C Control < 9%

HbA1C Control < 9%

Description

Measure identifies patients 18 years of age and older with diabetes who have had an annual hemoglobin A1C screening with a hemoglobin A1c value less than 9%.

Patient Identification

Age: 18+

Diagnosis: An active diagnosis of diabetes on the patient's Problem list or history of diabetes as indicated by a diagnosis code

Encounter: An encounter in the last 24 months

Not included in population: Patients diagnosed with gestational diabetes or steroid-induced diabetes

Measure Satisfaction

Measure is satisfied by the receipt of a lab result with hemoglobin A1c level less than 9%. This is automatically determined for labs received via an electronic interface. For lab values on paper, the A1c value can be manually entered by clicking "Edit Document" on the lab results document. The analyte must have "A1c" in its name to be recognized.

[Learn more about this measure](#)

Developer

American Diabetes Association (ADA)

Release/Revision Date

01/01/2017

Bibliographic Citation

American Diabetes Association. Glycemic targets. Sec. 6. In Standards of Medical Care in Diabetes - 2017. Diabetes Care 2017;40 (Suppl. 1):S48-S56.

athena updated: 4/2017

Dilated Eye Exam (annual)

Dilated Eye Exam (annual)

Description

Measure identifies patients 18 years of age and older with diabetes who have had a dilated eye exam.

Patient Identification

Age: 18+

Diagnosis: An active diagnosis of diabetes on the patient's Problem list or history of diabetes as indicated by a diagnosis code

Encounter: An encounter in the last 24 months

Not included in population: Patients diagnosed with gestational diabetes or steroid-induced diabetes

Measure Satisfaction

Measure is satisfied by one of the following in the last 12 months:

- Billing a dilated eye exam based on claims data (*CPT: 67028, 67030, 67031, 67036, 67038, 67039, 67040, 67041, 67042, 67043, 67101, 67105, 67107, 67108, 67110, 67112, 67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019, 92225, 92226, 92260*)
- Receiving a result for a Diabetic Ophthalmology Referral
- Indicating the result (positive or negative) and the date the eye exam was performed in the Quality Management Section

[Learn more about this measure](#)

Developer

American Diabetes Association (ADA)

Release/Revision Date

01/01/2017

Bibliographic Citation

American Diabetes Association. Glycemic targets. Sec. 6. In Standards of Medical Care in Diabetes - 2017. Diabetes Care 2017;40 (Suppl. 1):S109.

athena updated: 4/2017

Note: Hypertension (HTN): Controlling High Blood Pressure. In accordance with JNC8 recommendations two guidelines are listed in Athena with different target BP. For the 18-59 year old age group the target is <140/90; for the 60 years and older age group the target is <150/90. However, CMS for our annual GPRO reporting continues to use JNC7 target of <140/90 for both age groups.

Hypertension: BP control 140/90 (18-59 yrs)

Hypertension: BP control 140/90 (18-59 yrs)

Description

Measure identifies patients 18 through 59 years of age with hypertension whose most recent blood pressure is less than 140/90 mmHg.

Patient Identification

Age: 18-59

Encounter: An encounter during the reporting period

Diagnosis/Problem: Hypertension

Not included in population: Patients with diabetes, chronic kidney disease, or end stage renal disease

Measure Satisfaction

Measure is satisfied if the most recent blood pressure reading entered in the corresponding blood pressure fields in the Vitals section of a relevant encounter is less than 140 over 90 mmHg.

[Learn more about this measure](#)

Developer

Joint National Committee (JNC 8)

Release/Revision Date

02/05/2014

Bibliographic Citation

James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427.

athena updated: 2/2016

Hypertension: BP control 150/90 (60+ yrs)

Hypertension: BP control 150/90 (60+ yrs)

Description

Measure identifies patients 60 years of age or older with hypertension whose most recent blood pressure is less than 150/90 mmHg.

Patient Identification

Age: 60+

Encounter: An encounter during the reporting period

Diagnosis/Problem: Hypertension

Not included in population: Patients with diabetes, chronic kidney disease, or end stage renal disease

Measure Satisfaction

Measure is satisfied if the most recent blood pressure reading entered in the corresponding blood pressure fields in the Vitals section of a relevant encounter is less than 150 over 90 mmHg.

[Learn more about this measure](#)

Developer

Joint National Committee (JNC 8)

Release/Revision Date

02/05/2014

Bibliographic Citation

James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427.

athena updated: 2/2016

Oral Antiplatelet Therapy in CAD

Oral Antiplatelet Therapy in CAD

Description

Measure identifies patients 18 years of age and older with coronary artery disease who were prescribed antiplatelet medication.

Patient Identification

Age: 18+

Encounter: An encounter during the reporting period.

Diagnosis: An active diagnosis of coronary artery disease on their problem list.

Measure Satisfaction

Measure is satisfied if there is a new prescription or an active prescription on the patient's medication list for an antiplatelet medication.

[Learn more about this measure](#)

Developer

American Heart Association

Release/Revision Date

01/09/2012

Bibliographic Citation

American Heart Association. Advances in Interventional Cardiology: New Directions in Antiplatelet Therapy. Jan 2012.

athena updated: 2/2015